Cardiology prior authorization at Horizon Blue Cross Blue Shield of New Jersey
PA workflow, documentation criteria, and peer-to-peer prep — for prescribers and PA staff
Horizon Blue Cross Blue Shield of New Jersey cardiology PA at a glance
Horizon Blue Cross Blue Shield of New Jersey reviews cardiology PA submissions against its medical policy library, with rules drawn primarily from ACC/AHA Joint Guidelines + ESC equivalents for international references. Horizon Blue Cross Blue Shield of New Jersey-specific context: Only BCBS licensee in New Jersey; ~3.7M members. OMNIA Health Plans (tiered network) generate frequent appeals — tier-2 hospital usage carries higher cost share. NJ DOBI oversight; NJ has a strong external review program (IHCAP via Maximus).
Documentation packet — what to send
- Diagnosis with ICD-10 (HF with reduced/preserved EF, ATTR-CM, ASCVD)
- Most recent echocardiogram with EF, strain, valvular function
- LDL on maximally-tolerated statin (for PCSK9)
- BNP/NT-proBNP
- Documented adverse effect or contraindication to step-therapy alternatives
Common denial patterns to pre-empt
Patterns observed in cardiology across payers, and where Horizon Blue Cross Blue Shield of New Jersey's book of business overlaps:
- PCSK9 inhibitors: LDL threshold + maximally-tolerated statin not met
- Tafamidis: ATTR-CM diagnosis not confirmed by scintigraphy or biopsy
- Entresto: NYHA II-IV with reduced EF documentation missing
- Anticoagulant DOAC vs warfarin step therapy
- Step therapy on biologics
Appeal angles when Horizon Blue Cross Blue Shield of New Jersey denies
- ACC/AHA guideline class I recommendation citation
- Cardiovascular outcome trial (FOURIER, PARADIGM-HF, EMPEROR, DAPA-HF) by name
- Imaging or biomarker evidence (BNP, ejection fraction, scintigraphy grade)
- Statin intolerance documentation per NLA Position Paper
Peer-to-peer prep
- Have echo with EF and the latest LDL panel open
- Quote the guideline Class I recommendation with reference number
- For PCSK9: explicitly state 'maximally tolerated statin' — payers reject 'tried and failed' wording
- For ATTR-CM: confirm whether the diagnosis was scintigraphy-based or biopsy-based — affects PA criteria
Drug-specific PA criteria at Horizon Blue Cross Blue Shield of New Jersey
Deep dives on each drug's PA criteria at Horizon Blue Cross Blue Shield of New Jersey:
Frequently asked questions
What documentation does Horizon Blue Cross Blue Shield of New Jersey need for cardiology prior authorizations?
Horizon Blue Cross Blue Shield of New Jersey's PA packet for cardiology typically includes: Diagnosis with ICD-10 (HF with reduced/preserved EF, ATTR-CM, ASCVD); Most recent echocardiogram with EF, strain, valvular function; LDL on maximally-tolerated statin (for PCSK9); BNP/NT-proBNP. ACC/AHA Joint Guidelines + ESC equivalents for international references citations strengthen the submission.
What's the turnaround at Horizon Blue Cross Blue Shield of New Jersey?
Horizon Blue Cross Blue Shield of New Jersey standard decision: 30 days. Expedited (urgent care): 72 hours per 45 CFR §147.136. Internal appeal window if denied: 180 days.
Which cardiology drugs does Horizon Blue Cross Blue Shield of New Jersey most often PA-restrict?
Top targets in cardiology: apixaban, rivaroxaban, evolocumab, sacubitril valsartan, tafamidis. Each follows the per-drug step therapy + documentation requirements published in Horizon Blue Cross Blue Shield of New Jersey's medical policy library.
How do I prep a peer-to-peer with Horizon Blue Cross Blue Shield of New Jersey in cardiology?
Have echo with EF and the latest LDL panel open Quote the guideline Class I recommendation with reference number Have the policy URL and the patient's chart open before the call.
Generate a Cardiology PA packet
Open ApprovalHelp — generate a cardiology PA packet tailored to Horizon Blue Cross Blue Shield of New Jersey's criteria, with prescriber attestation and supporting citations pre-filled.
Get started →Contact: hello@approvalhelp.com